SCHEMBL7446390

SCHEMBL7446390

Cc1ccc(C(=O)N2CCC(=O)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.65
ALDH1A1 P00352 2/20 0.65
HPGD P15428 2/20 0.64
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
LMNA P02545 3/20 0.54
GABRD O14764 1/20 0.54
GABRA1 P14867 1/20 0.54
GABRB1 P18505 1/20 0.54
GABRA5 P31644 1/20 0.54
GABRA3 P34903 1/20 0.54
GABRA2 P47869 1/20 0.54
GABRB2 P47870 1/20 0.54
GABRA4 P48169 1/20 0.54
GAA P10253 1/20 0.51
HSD11B1 P28845 1/20 0.51
MGLL Q99685 1/20 0.51
SLC6A7 Q99884 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL8380995 0.96 PKM (0.61) PKMALDH1A1HPGDMEN1KMT2A
SCHEMBL13211827 0.93 ALDH1A1 (0.57) PKMALDH1A1HPGDMEN1KMT2A
SCHEMBL24120195 0.90 HPGD (0.61) PKMALDH1A1HPGDMEN1KMT2A
SCHEMBL10726712 0.86 ALDH1A1 (0.84) PKMALDH1A1HPGDMEN1KMT2A
SCHEMBL4557193 0.86 ALDH1A1 (0.84) PKMALDH1A1HPGDMEN1KMT2A
SCHEMBL14817953 0.84 ALDH1A1 (0.62) PKMALDH1A1HPGDMEN1KMT2A
SCHEMBL2987838 0.83 MTHFD2 (0.54) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL27811868 0.83 HPGD (0.53) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL10192065 0.82 ALDH1A1 (0.71) PKMALDH1A1HPGDMEN1KMT2A
SCHEMBL1753628 0.82 HPGD (0.76) PKMALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834521-B2 Choline kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20160024024-A1 Novel Choline Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2016-01-28 US disclosed
WO-2014151761-A1 NOVEL CHOLINE KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2014-09-25 WO disclosed
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-7598382-B2 Aryl substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-10-06 US disclosed
US-7598382-B2 Aryl substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-10-06 US disclosed
US-20090075995-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2009-03-19 US disclosed
WO-2008151184-A1 BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME VANDERBILT UNIVERSITY (US) 2008-12-11 WO disclosed
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2007-11-08 US disclosed
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2007-11-08 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed
WO-2007075468-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-07-05 WO disclosed
CN-1204327-A Pharmaceutically active quinazoline compounds ASTRA PHARMA PROD (GB) 1999-01-06 CN disclosed
CN-1040873-C Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing these compounds and .... THOMAE GMBH DR K (DE) 1998-11-25 CN disclosed
US-5466687-A Anticholesterol agents DR. KARL THOMAE GMBH (DE) 1995-11-14 US disclosed
EP-0596326-B1 Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production THOMAE GMBH DR K (DE) 1995-08-23 EP disclosed
EP-0596326-A1 Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production Dr. Karl Thomae GmbH (DE) 1994-05-11 EP disclosed
US-4499100-A CARDIOUVASCULAR DISORDERS SYNTEX (U.S.A.) INC. (US) 1985-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024024-A1 Novel Choline Kinase Inhibitors CHKA, CHKB, CEPT1 PKM 491/4885ALDH1A1 2140/4885HPGD 2170/4885
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES IL2, TSLP, IFNG PKM 2767/4885ALDH1A1 521/4885HPGD 773/4885
US-20090075995-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFKB2, NFRKB, NFKB1 PKM 3215/4885ALDH1A1 3409/4885HPGD 3452/4885
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 PKM 3823/4885ALDH1A1 1178/4885HPGD 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.